<DOC>
	<DOCNO>NCT01723072</DOCNO>
	<brief_summary>This study assess impact omalizumab quality life improvement add standard therapy refractory patient suffer chronic spontaneous urticaria angioedema .</brief_summary>
	<brief_title>Impact Omalizumab Quality Life Measures Angioedema Occurrence Patients With CSU Refractory Therapy</brief_title>
	<detailed_description>This study conduct use double-blind , placebo-controlled , randomize , multicenter design investigate impact omalizumab Quality Life ( QoL ) Chronic Spontaneous Urticaria ( CSU ) ass effectiveness reduce and/or inhibit occurrence , time-course severity angioedema episode . Omalizumab administer subcutaneously every 4 week add-on therapy current approve treatment adult CSU patient . The treatment period 28 week follow 8-week follow-up . The study aim enroll approximately 70 patient . The study divide 2-week screening period , 28-week double-blind treatment phase omalizumab placebo-omalizumab , 8-week follow-up phase .</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis chronic spontaneous urticaria ( CSU ) refractory H1antihistamine treatment Presence itch hive 6 week UAS7 score 14 ( range 042 ) Patient history insufficient response 4x approve dose H1antihistamines CSU diagnosis 6 month Angioedema least 4x last 6 month Patients non urticaria associate angioedema History hypersensitivity omalizumab rescue medication drug similar chemical structure Evidence parasitic infection Previous treatment omalizumab within last 6 month prior screen History anaphylactic shock Woman pregnant breast feed Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Chronic spontanous urticaria , refractory CSU , Angioedema</keyword>
</DOC>